These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 12435170

  • 1. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA, Tchekmedyian NS.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [Abstract] [Full Text] [Related]

  • 2. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Oct; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 3. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia.
    Jumbe N, Yao B, Rovetti R, Rossi G, Heatherington AC.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):37-44. PubMed ID: 12435172
    [Abstract] [Full Text] [Related]

  • 4. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 5. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Oct; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 6. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 7. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Dec; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 9. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
    Vansteenkiste J, Poulsen E, Rossi G, Glaspy J.
    Oncology (Williston Park); 2002 Oct 15; 16(10 Suppl 11):45-55. PubMed ID: 12435173
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 15; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 11. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Jun 15; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 15; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 13. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 15; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 14. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep 15; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Sep 15; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 16. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May 15; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 17. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan 15; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 18. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J.
    Oncology (Williston Park); 2006 Jul 15; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J, Reeves T, Wallace J.
    Oncologist; 2004 Jul 15; 9(4):451-8. PubMed ID: 15266098
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.